Scholars Central

Short communicationPublished 2017

Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Authors: Caibao Jin, Qing Li, Xiaojian Zhu, Li Meng

Chemotherapy: Open Access

Volume 6 · Issue 1 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Stopping tyrosine kinase inhibitors (TKIs) treatment is an emerging goal of chronic myeloid leukemia (CML) management. Several studies have demonstrated the feasibility of stopping treatment. A sustained molecular response on long-term TKIs therapy seems to be necessary prior to attempting treatment-free remission (TFR). However, there were none available characteristics or indicators which can predict the outcome of TKIs discontinuation now. In our opinion, factors which could reflex the progression probability of minimal residual leukemia such as leukemia stem cells and microenvironment might play a pivotal role. Besides, novel methods for further monitoring would also attract much attention of the researchers in this area.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Chemotherapy: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalChemotherapy: Open Access
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Caibao Jin”
  • BylineArticles whose byline prints “Qing Li”
  • BylineArticles whose byline prints “Xiaojian Zhu”
  • BylineArticles whose byline prints “Li Meng”